Results 191 to 200 of about 81,406 (283)

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources

Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer. [PDF]

Breast Cancer Res Treat
Amniouel S, Jafri MS.
europepmc   +1 more source

Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC

Cancer Science, Volume 117, Issue 5, Page 1273-1285, May 2026.
Our work makes the proof of concept that there is a clinical benefit to target both PRMT1 and PRMT5 to maximize the anti‐tumoral effect of chemotherapy in triple negative breast cancer. ABSTRACT Patients with triple‐negative breast cancer (ER−, PR−, and HER2−) are routinely treated with chemotherapies that induce DNA damage.
Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El‐Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis, Coralie Poulard, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer   +13 more
wiley   +1 more source

Nomograms for the prognosis prediction model of early-stage triple-negative breast cancer - based on SEER database. [PDF]

Future Sci OA
Wang Y, Li F.
europepmc   +1 more source

YTHDF3 Mediates the Occurrence and Development of Breast Cancer by Regulating Glycolysis Through the mTOR–HIF1α–LHDA Axis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Breast cancer, a malignant tumour that frightens women, ruthlessly claims the lives of tens of thousands of women around the world every year. However, the mechanism by which YTHDF3 regulates the occurrence and development of breast cancer is still imperfect.
ZiQian Liu, TengFei Jiang, Peng Li, Ke Dong, XiMei Wang, ChenChen Geng, XiaoDong Zhang, Dan Zuo, GuangHui Zhao   +8 more
wiley   +1 more source

CXCL1 in triple‑negative breast cancer: Mechanisms, challenges, and therapeutic opportunities (Review). [PDF]

Oncol Rep
Al Sayegh H, Assi Z, Kanaan A, El Sibai M.   +3 more
europepmc   +1 more source

SORBS2: A Molecular Nexus in Multisystem Diseases Through Scaffold‐Mediated Regulation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Sorbin and SH3 Domain Containing 2 (SORBS2), a multifunctional scaffold protein harbouring Sorbin homology (SoHo) and Src homology 3 (SH3) domains, serves as a molecular hub in human diseases by integrating cytoskeletal remodelling, signal transduction and RNA metabolic regulation. This study systematically analyses SORBS2's molecular features,
Qiwei Jia, Yong Zhang
wiley   +1 more source

Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression. [PDF]

Breast Cancer (Dove Med Press)
Behar J, Shiang C, Dolcen DN, Bennett LB, DeVilbiss AW, Matossian MD, Chan IS, Nanda R, Conzen SD, Lafin JT.   +9 more
europepmc   +1 more source

Design, Synthesis, and Biological Evaluation of Novel Triazine‐Based Dual Histone Deacetylase/phosphatidylinositol 3‐kinase Inhibitors for Breast Cancer Therapy

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Breast cancer is the most frequently diagnosed malignancy and a leading cause of cancer‐related mortality among women worldwide. Triple‐negative breast cancer (TNBC) poses a major clinical challenge due to its aggressive nature, limited therapeutic options, and high propensity for drug resistance.
Lara Luzietti, Gustavo Salgado Pires, Ana Ryan, Crisamie Regidor, Matthew Hiller, Danilo Sarti, Tríona Ní Chonghaile, Pedro de Sena Murteira Pinheiro, Damir Varešlija, Daniel Alencar Rodrigues   +9 more
wiley   +1 more source

PD-L1-negative triple-negative breast cancer exhibited a remarkable response to cadonilimab: a case report. [PDF]

Front Oncol
Chen B, Jia Y, Meng L, Hu N.
europepmc   +1 more source